Flossbach Von Storch SE boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,335,285 shares of the medical research company's stock after buying an additional 7,140 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.8% of Flossbach Von Storch SE's investment portfolio, making the stock its 15th largest position. Flossbach Von Storch SE owned 0.35% of Thermo Fisher Scientific worth $694,655,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the business. AMF Tjanstepension AB bought a new position in Thermo Fisher Scientific during the 3rd quarter worth $42,409,000. Howard Capital Management Group LLC raised its position in shares of Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock worth $33,759,000 after acquiring an additional 286 shares during the last quarter. Symphony Financial Ltd. Co. lifted its stake in shares of Thermo Fisher Scientific by 142.9% in the third quarter. Symphony Financial Ltd. Co. now owns 1,394 shares of the medical research company's stock worth $856,000 after acquiring an additional 820 shares during the period. Westhampton Capital LLC increased its position in Thermo Fisher Scientific by 1.4% during the 3rd quarter. Westhampton Capital LLC now owns 2,217 shares of the medical research company's stock valued at $1,371,000 after purchasing an additional 30 shares during the period. Finally, Private Advisor Group LLC raised its holdings in Thermo Fisher Scientific by 1.2% during the 3rd quarter. Private Advisor Group LLC now owns 22,127 shares of the medical research company's stock worth $13,686,000 after purchasing an additional 271 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Thermo Fisher Scientific Stock Down 1.0 %
TMO stock traded down $5.28 during mid-day trading on Friday, reaching $532.55. 1,613,862 shares of the company traded hands, compared to its average volume of 2,087,588. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm's 50 day moving average price is $548.36 and its 200 day moving average price is $568.15. The stock has a market cap of $203.70 billion, a price-to-earnings ratio of 32.22, a P/E/G ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific declared that its board has authorized a share buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are often a sign that the company's leadership believes its shares are undervalued.
Thermo Fisher Scientific Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.32%. Thermo Fisher Scientific's payout ratio is 9.44%.
Insiders Place Their Bets
In other news, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now directly owns 16,363 shares of the company's stock, valued at $9,582,009.17. This represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,125 shares of company stock valued at $11,231,699. Corporate insiders own 0.34% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on TMO shares. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $630.00 to $620.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Scotiabank increased their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a report on Monday, February 3rd. Robert W. Baird cut their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. StockNews.com upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, January 14th. Finally, Bank of America cut their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $658.00.
Check Out Our Latest Stock Analysis on Thermo Fisher Scientific
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
